The molecular role of Serf2 in development and misfolded protein aggregation

Stroo, E., 2018, [Groningen]: Rijksuniversiteit Groningen. 181 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 1 MB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 19 MB, PDF document

  • Chapter 3

    Final publisher's version, 9 MB, PDF document

  • Chapter 4

    Final publisher's version, 14 MB, PDF document

  • Chapter 5

    Final publisher's version, 16 MB, PDF document

  • Chapter 6

    Final publisher's version, 1 MB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Chapter 8

    Final publisher's version, 1 MB, PDF document

  • Appendices

    Final publisher's version, 1 MB, PDF document

  • Complete thesis

    Final publisher's version, 59 MB, PDF document

  • Propositions

    Final publisher's version, 42 KB, PDF document

  • Esther Stroo
Protein aggregation in the brain is a common hallmark of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The biological mechanism of protein aggregation remains unresolved. This thesis describes the function of an enhancer of protein aggregation, Serf2, in development and in a model for Alzheimer's disease.
Loss of Serf2 in mice leads to neonatal death and reduced body weight and size. Pathological analyses reveals less matured lung tissue, and as a result the mice without Serf2 are not able to breath after birth and die. Cells of these mice also grow slower, and show a change in the genes that regulate cell cycle. These findings show that Serf2 is important for embryonic growth and viability, by a direct or indirect role in cell division.
Serf2 can directly affect protein aggregation of disease proteins in a test tube. To discover if absence of Serf2 has an effect on disease pathology, we deleted Serf2 in the brain of an Alzheimer mouse model. Loss of Serf2 does not affect the Alzheimer pathology quantitatively but appears to change the morphology to more compact and less regular structures. Others have correlated such structural differences to Alzheimer disease severity. Based on our results it is possible that inherited factors like Serf2 drive these changes, which would make them a target to actively redirect disease proteins to more benign lesions.
More research will be required to determine the consequences of the structural changes for the health of the brain, before Serf2 inhibition can be explored as a therapeutic intervention.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date7-May-2018
Place of Publication[Groningen]
Print ISBNs978-94-034-0568-1
Electronic ISBNs978-94-034-0567-4
Publication statusPublished - 2018

Download statistics

No data available

ID: 56763635